Company Encyclopedia
View More
name
Ligand Pharmac-B
LGND.US
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis.
4.499 T
LGND.USMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking15/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5.42%C
    • Profit Margin19.34%A
    • Gross Margin78.50%A
  • Growth ScoreA
    • Revenue YoY64.83%A
    • Net Profit YoY7.38%C
    • Total Assets YoY54.66%A
    • Net Assets YoY12.96%B
  • Cash ScoreB
    • Cash Flow Margin517.14%C
    • OCF YoY64.83%A
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreB
    • Gearing Ratio35.66%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ligand Pharmaceuticals Director John W. Kozarich Reports Sale of Common Shares

    John W. Kozarich, Director at Ligand Pharmaceuticals Inc., has reported the sale of common shares of the company, as per a recent SEC filing. This information was disclosed through EDGAR, the SEC's Electronic Data Gathering, Analysis, and Retrieval system. The original content was published by Ligand Pharmaceuticals Inc. on December 03, 2025.

    Reuters·
    US
    LGND
    -1.93%
    Reuters·
    US
    LGND
    -1.93%

    Ligand Pharmaceuticals Director John L. LaMattina Reports Disposal of Common Shares

    John L. LaMattina, Director of Ligand Pharmaceuticals Inc., reported the disposal of common shares. The full filing is accessible via the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice. The original content was published by Ligand Pharmaceuticals via EDGAR on November 12, 2025.

    Reuters·
    US
    LGND
    -1.93%
    Reuters·
    US
    LGND
    -1.93%

    Ligand Pharmaceuticals’ Earnings Call Highlights Strong Growth

    Ligand Pharmaceuticals Inc. reported strong Q3 earnings, with core revenue up 68% year-over-year to $86.9 million and adjusted EPS also rising 68% to $3.09. The company raised its full-year 2025 guidance, expecting core revenue between $225 million and $235 million. Ligand completed a $460 million convertible note financing to strengthen its capital position. Despite increased operating expenses, the overall outlook remains positive, with expectations of long-term royalty growth exceeding 22% CAGR by 2029. Concerns include rising expenses and limited details on the ZELSUVMI launch, with more information expected on November 13.

    Tip Ranks·
    US
    LGND
    -1.93%
    Tip Ranks·
    US
    LGND
    -1.93%

    Ligand Pharmac-B | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 115.46 M

    LB filings·
    US
    LGND
    -1.93%
    LB filings·
    US
    LGND
    -1.93%

    Benchmark Co. Sticks to Its Buy Rating for Ligand Pharma (LGND)

    Benchmark Co. has maintained a Buy rating on Ligand Pharma (LGND) with a price target of $220.00, according to analyst Robert Wasserman. He has an average return of 16.7% and a 47.70% success rate on his stock recommendations. Additionally, H.C. Wainwright's Joseph Pantginis also issued a Buy rating for Ligand Pharma, while TR | OpenAI reiterated a Hold rating.

    Tip Ranks·
    US
    LGND
    -1.93%
    Tip Ranks·
    US
    LGND
    -1.93%
    © 2025 Longbridge｜Disclaimer